Valuation: SANOFI

Market Cap 92.83B 106B 85.66B 78.95B 149B 10,229B 152B 1,024B 403B 5,010B 399B 390B 17,246B P/E 2026 *
11.7x
P/E 2027 * 10.7x
Enterprise Value 102B 117B 94.54B 87.15B 164B 11,290B 168B 1,130B 444B 5,530B 440B 431B 19,036B EV / Sales 2026 *
2.18x
EV / Sales 2027 * 1.97x
Free-Float
89%
Yield 2026 *
5.5%
Yield 2027 * 5.83%
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 57 2020-04-27
Director/Board Member 64 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 106B
+0.85%-0.80%+54.84%+163.70% 1,043B
+1.23%-1.53%+55.26%+59.07% 602B
+0.04%+2.58%+32.96%+88.75% 449B
+0.78%-0.71%+30.04%+24.61% 327B
+1.41%+0.58%+33.92%+47.20% 279B
-0.27%-1.87%+22.13%+23.47% 264B
-1.76%+2.37%-22.19%-38.45% 227B
-1.42%+0.80%+22.81%+60.77% 201B
-1.48%+3.43%+23.42%+73.31% 169B
Average -0.11%+0.61%+28.13%+55.82% 395.69B
Weighted average by Cap. +0.20%+0.04%+37.59%+81.26%

Financials

2026 *2027 *
Net sales 46.95B 53.73B 43.33B 39.94B 75.27B 5,174B 76.94B 518B 204B 2,534B 202B 197B 8,723B 50.04B 57.26B 46.17B 42.56B 80.22B 5,514B 82B 552B 217B 2,701B 215B 210B 9,296B
Net income 7.99B 9.14B 7.37B 6.8B 12.81B 881B 13.09B 88.13B 34.66B 431B 34.34B 33.58B 1,485B 8.9B 10.19B 8.22B 7.57B 14.27B 981B 14.59B 98.19B 38.62B 480B 38.26B 37.42B 1,654B
Net Debt 9.63B 11.02B 8.89B 8.19B 15.44B 1,061B 15.78B 106B 41.78B 520B 41.39B 40.48B 1,789B 5.52B 6.32B 5.09B 4.69B 8.85B 608B 9.04B 60.88B 23.94B 298B 23.72B 23.2B 1,025B
Logo SANOFI
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA